anticancer agent 7

Anticancer agent 7 (Example 5) is a potent anti-cancer compound with an IC50 value of 5 μM against H1650 lung cancer cells.

Anticancer agent 73 is an anticancer agent which potently targets transactivation response(TAR) RNA-binding protein 2 (TRBP) and disrupts the TRBP-Dicer interaction. Anticancer agent 73 suppresses the growth and metastasis of HCC in vitro and in vivo by modulating expression profiles of miRNAome and proteome in HCC cells.

Anticancer agent 75 has good antiplasmodial activity. Anticancer agent 75 is a potent anticancer agent with cytotoxicity and selectivity in cancer cell lines. The cytotoxicity of Anticancer agent 75 to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard [1].

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 72 (compound 8c) effectively inhibits the K+ channel and induces apoptosis, displaying significant potential as an anticancer treatment [1].

Anticancer agent 78 has anti-aromatase activity (IC50=0.9 μM). Anticancer agent 78 is an effective anticancer agent, showing cytotoxicity. Anticancer agent 78 has research potential in breast cancer.

Anticancer agent 79 (compound 3d) is an anticancer compound with good anti-breast cancer activity, exhibiting cytotoxic activity in T47-D cells (IC50= 13.64 ± 0.26 μM).

Anticancer agent 71 (Compound 4b) is a potent anticancer agent that arrests the cell cycle at the G2/M phase and induces apoptosis by upregulating Bax, Ikb-α, and cleaved PARP, while downregulating Bcl-2 expression levels.

Anticancer agent 77 exhibits anticancer effects and can be used extensively in synthetic and medicinal chemistry studies.

Anticancer agent 76 (Compound CT2-3) significantly inhibits proliferation, induces cell cycle arrest, ROS production, and apoptosis in human NSCLC cells.

1. Octyl Gallate is an antioxidant approved by the US Food and Drug Administration (FDA) as a food additive. 2. Octyl Gallate has antimetastatic activity. 3. Octyl Gallate shows antimicrobial activity against H. pylori, with a minimum inhibitory concentration (MIC) value of 125 ug/mL. 4. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.5. Octyl Gallate is a potential anticancer agent, it exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of 40 uM. 6. Octyl gallate (Octyl 3,4,5-trihydroxybenzoate) has antiviral activity, it shows an inhibitory effect on the growth of herpes simplex virus type 1 (HSV-1) in HEp-2 or Vero cells. 7. Octyl gallate shows antifungal activity against Saccharomyces cerevisiae ATCC7754 and Zygosaccharomyces bailii ATCC 60483.

Antiproliferative agent-22 is an anticancer compound that shows antiproliferative activity on MCF-7, MDA-MB-231, and MDA-MB-468 cells.Antiproliferative agent-22 is used in cancer research.

Antiproliferative agent-16 (Antiproliferative agent-16) is an indolyl hydrazide-hydrazone compound with anticancer activity. Antiproliferative agent-16 exhibits specificity toward breast cancer cells (IC50 of 6.94 μM for MCF-7 cells).

Antiproliferative agent-59 (Compound 14u) acts as an inhibitor of tubulin polymerization. Demonstrating anticancer activity in Huh7, SGC-7901, and MCF-7 cell lines, this compound achieves IC50 values of 0.03, 0.18, and 0.13 μM, respectively. Additionally, it arrests the cell cycle at the G2 M phase and induces apoptosis in Huh7 cells. In a xenograft mouse model utilizing Huh7 cells, Antiproliferative agent-59 exhibits antitumor effects against hepatocellular carcinoma without significant toxicity.

Apoptosisinducer 30 (Compound 15a) acts as an anticancer agent. It induces apoptosis in MCF-7 cells through the mitochondrial pathway. This compound elevates intracellular levels of reactive oxygen species (ROS), decreases mitochondrial membrane potential, and arrests the cell cycle at the G0 G1 phase. Apoptosisinducer 30 inhibits cell growth, with an IC50 value of 0.32 μM against MCF-7 cells, and suppresses tumor growth in a mouse breast cancer model.

Antiangiogenic agent 7 (Compound 1) induces apoptosis, elevates Reactive Oxygen Species (Reactive Oxygen Species), and inhibits the intracellular enzyme thioredoxin reductase. It exhibits anticancer activity with IC50 values ranging from 0.08 to 3.5 μM against cervical cancer cells (HeLa), prostate cancer cells (PC-3), and non-small cell lung cancer cells (A549). Additionally, Antiangiogenic agent 7 suppresses tumor growth in a mouse xenograft model.

Anticanceragent 263 (compound 7) is an effective anticancer agent. It binds with the G-quadruplex DNA (G4) sequence 22-mer Pu22 (a c-Myc DNA analog). As a structural modulator, Anticanceragent 263 significantly enhances the formation of protein α-helices and has the capacity to form a supramolecular network. Furthermore, Anticanceragent 263 exhibits no cytotoxicity.

Antitumor agent-196 (Compound 6a (β, β, β)) is an artemisinin-based oligomer with anticancer properties, exhibiting an IC50 of 90 nM against MCF-7 breast cancer cells. This compound induces apoptosis by modulating the Bax-caspase 3 signaling pathway and triggers ferroptosis by regulating key signaling molecules (including GPX4). Antitumor agent-196 shows potential for cancer research applications.

Anticanceragent 266 (Compound 3B) is an anticancer agent that inhibits the proliferation of tumor cells. It has an IC50 of 0.13 μM against the MCF-7 breast cancer cell line.

Antimicrobial agent-40 exhibits antibacterial activity against fungi, Gram-negative, and Gram-positive bacteria. It also shows anticancer properties, displaying significant cytotoxicity towards MCF-7 cells with an IC50 of 33.52 μM.

Anticanceragent 187 (Compound 4) is an anticancer agent that targets sarcoma cells in tumor-bearing mouse models. It exhibits cytotoxicity against HepG2, Caco2, and MCF-7 cell lines.

anti-TNBC agent-7 (Compound 13c) exhibits anticancer activity and functions as a molecular probe to identify and regulate the signaling of the USP21/JAK2/STAT3 axis. It demonstrates nanomolar cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC).

Anticanceragent 221 (Compound 4h) is an orally active anticancer and antioxidant agent. It exhibits cytotoxicity against cancer cells A549 (IC50=22.09 µg/mL) and MCF-7 (IC50=6.40 µg/mL) and induces apoptosis. It demonstrates antioxidant activity with an IC50 of 42.46 μM in the DPPH assay. In mouse models, Anticanceragent 221 shows antitumor efficacy against breast cancer.